Updated trials into retatrutide, a dual GIP and GLP-1 compound, are demonstrating significant potential for metabolic therapy. Initial clinical assessments have revealed substantial reductions in physical weight and improvements in connected glycemic indicators , particularly for individuals with obesity . Future pursuits focus on assessing the lo